H

umans have been “repurposing” for centuries. Today we turn old churches into museums, schoolhouses into condos, old tires into artificial turf, and plastic bottles into dress pants. Drugs have become a new and exciting target for this activity.

Two high-profile examples in the drug world are sildenafil and minoxidil. Both began as medications for cardiovascular issues. But along the way, it became clear that they did other things even better. Sildenafil, rebranded as Viagra, helps some men with erectile dysfunction get and sustain erections. Minoxidil helps hair grow, which spawned Rogaine.

Finding new uses for existing medications makes good sense. The cost to develop a new drug is astounding, ranging from $1 billion to $2 billion, and it takes 10 to 12 years or more to go from the lab to the clinic. Only about 10 percent of new drugs and biologics are approved, and fewer than 20 percent of them generate enough revenue to cover the cost of research and development.

advertisement

Repurposing can save time and money in developing treatments for diseases that don’t have effective therapies. Another advantage is that the side effects of the “old” drug are already well-known.

A new life for ketamine

Fifty years ago, I was part of a team at Parke-Davis (once America’s oldest and largest pharmaceutical company) that developed a new drug called ketamine as an anesthetic agent. The FDA approved it in 1970. I’ve been keeping an eye on this medication ever since. Ketamine blocks a glutamate receptor known as NMDA. This receptor is involved in pain transmission and other activities of the central nervous system, including memory, cognition, and sensory functions such as hearing.

My research team at the Texas A&M Health Science Center is one of several looking at ketamine for new uses, such as treating tinnitus (ringing in the ears), major depression, and chronic pain. Chronic pain and depression often coexist; when depression improves, people often tolerate pain better.

No drugs are currently approved to treat tinnitus. It affects more than 15 million Americans, including soldiers who have been on the battlefield, teenagers who use headphones at high volumes, industrial workers who experience high levels of ambient noise, and the elderly. Ketamine could be a safe treatment for this potentially aggravating condition.

Although numerous drugs are available to treat depression, they don’t always work. Antidepressants like Prozac, Zoloft, or Effexor can take weeks or months to ease depression, if they work at all. Ketamine acts quickly to relieve depression and ease suicidal thoughts, often having effects in minutes to hours.

Opioids such as morphine are powerful painkillers, but they can make a spinal cord injury worse. Sometimes they can even make pain worse. Opioids also can be addictive. Ketamine, despite its use as a street drug, isn’t thought to be addictive, but it might be habit-forming.

Beyond ketamine

We plan to test ketamine in combination with another existing drug, brimonidine, which is currently approved to treat glaucoma and rosacea. Our hope is that this combination will be better than ketamine alone for treating pain while canceling out negative side effects of each other.

There are a number of other promising candidates for repurposing: mecamylamine, ropinirole, and valsartan were all originally used for high blood pressure but are now being examined for treating depression, Parkinson’s disease, and Alzheimer’s disease, respectively. Tamoxifen, originally used for breast cancer, and amphotericin B, an antifungal drug, might both be useful in bipolar disorder.

As is the case for any drug, new or repurposed, there is always more to learn. But it makes sense to explore existing drugs for new indications as a way to improve treatment while reducing drug development time, cost, and risk of unexpected side effects.

David E. Potter, PhD, is professor and chair of pharmaceutical sciences at the Texas A&M Health Science Center Irma Lerma Rangel College of Pharmacy.

Leave a Comment

Please enter your name.
Please enter a comment.

  • This is very interesting and informative article. It is worthwhile to repurpose many Old drugs for treating new and unexplored indication. This will surely help mankind by reducing the cost of development of new drugs and eventually save the high cost of treatment for needy population. Thanks for delightful topic.

  • Big Pharma companies do this strictly to find new indications to extend the life of Dying Blockbusters via new FDA approvals. Or, they tweak an old, out-of-patent molecule to get a new patent, and achieve a new monopoly – as they are doing with Ketamine. When I see just ONE of theese re-purposed drugs left in the public domain, I’ll be shocked. Hasn’t happened yet.

  • This is an very interesting development with the use of a combination of ketamine and brimonidine and I wonder if this can help in depression also. I’ve found that using low dose sublingual ketamine reduces the side effect burden and is a more practical and affordable option to the injection approaches for patients suffering from treatment resistant depression. Further details can be found in the recently released book “Ketamine for Depression.”

  • Excellent article on a very important issue. You might also address the fact that 1 in 5 prescriptions in the US are off-label and the fact that a particular treatment isnt FDA approved is not because it doesnt work or is unsafe. At Ketamine Clinics of Los Angeles, we provide IV ketamine infusions to treat depression, ocd, ptsd, crps/rsd, and other chronic pain with an 80%+ success rate. Feel free to take a look at our website ketamineclinics.com to learn more about our treatment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.